PURPOSE:To investigate the role of quantitative pre-treatment dual-energy computed tomography (DECT) for prediction of loco-regional recurrence (LRR) in patients with larynx/hypopharynx squamous cell cancer (L/H SCC). METHODS:Patients with L/H SCC treated with curative intent loco-regional radiotherapy and that underwent treatment planning with contrast-enhanced DECT of the neck were included. Primary and nodal gross tumor volumes (GTVp and GTVn) were contoured and transferred into a Matlab® workspace. Using a two-material decomposition, GTV iodine concentration (IC) maps were obtained. Quantitative histogram statistics (maximum, mean, standard deviation, kurtosis and skewness) were retrieved from the IC maps. Cox regression analysis was conducted to determine potential predictive factors of LRR. RESULTS:Twenty-five patients, including 20 supraglottic and 5 pyriform sinus tumors were analysed. Stage I, II, III, IVa and IVb constituted 4% (1 patient), 24%, 36%, 28% and 8% of patients, ...

The aim of the present analysis was to evaluate the recurrence pattern in patients with recurrent malignant glioma after re-irradiation in combination with bevacizumab as there is limited data on how to optimally choose dose, fractionation and delineation margins. Thirty-one patients with recurrent malignant glioma treated with re-irradiation and bevacizumab after previous chemoradiotherapy (concurrent temozolomide 75 mg/m2/d according to the EORTC/NCIC trial) and [18 F]FET-PET and/or MRI confirmed recurrence were retrospectively analyzed. Bevacizumab was applied twice during fractionated re-irradiation (10 mg/kg, d1 + d15, median 36 Gy, conventionally fractionated). Recurrence patterns were assessed by means of [18 F]FET-PET and/or MRI. Median follow-up was 34.0 months for all patients [95%-CI, 27.7-40.3] and median post-recurrence survival 10.8 months [95%-CI, 9.2-12.4]. Concerning the recurrence patterns, 61.3% of these were located in-field (19 patients), 22.6% were marginal (7 patients) and 16.1%

TY - JOUR. T1 - A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix. T2 - A Gynecologic Oncology Group study. AU - Fiorica, James V.. AU - Blessing, John A.. AU - Puneky, Louis V.. AU - Secord, Angeles Alvarez. AU - Hoffman, James S.. AU - Yamada, S. Diane. AU - Buekers, Thomas E.. AU - Bell, Jeffrey. AU - Schilder, Jeanne M.. PY - 2009/11/1. Y1 - 2009/11/1. N2 - Purpose: To estimate antitumor activity and toxicity of weekly topotecan hydrochloride in patients with persistent or recurrent cervical carcinoma who failed prior treatment. Patients and methods: Women entered on study had or failed one prior chemotherapy regimen in addition to radiosensitizing chemotherapy, performance status less than 3, and adequate hematologic, renal, hepatic, and neurological function. Topotecan was infused at 3.0 mg/m2 on days 1, 8, and 15 every 28 days. Results: Twenty-seven patients were enrolled onto this study with 25 evaluable. ...

The 21-gene recurrence score significantly predicted the risk of recurrence and death in node-positive, estrogen receptor-positive patients treated with adjuvant chemoendocrine therapy, but it did not predict benefit from the addition of paclitaxel to the regimen in a subset of patients from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28 trial,1 according to Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, Professor of Surgery at Northeastern Ohio Universities College of Medicine and Medical Director of the Comprehensive Breast Program at MD Anderson Cancer Center, Orlando, Florida, and Chairman of the Breast Committee of the NSABP Operations and Biostatistical Center, Pittsburgh, Pennsylvania.. Study Goals. The goal of this substudy was to evaluate the recurrence score as a predictor of the risk of local-regional recurrence in node-positive, estrogen receptor-positive patients treated with adjuvant endocrine therapy and chemotherapy. The secondary goal was to evaluate ...

OBJECTIVES:. I. Compare overall survival in patients with locally advanced, metastatic, or recurrent colorectal cancer treated with fluorouracil, leucovorin calcium, oxaliplatin, and bevacizumab vs capecitabine, oxaliplatin, and bevacizumab.. II. Compare progression-free survival and time to treatment failure in patients treated with these regimens.. III. Compare the response of patients with measurable disease treated with these regimens.. IV.Compare toxicity rates of these regimens in these patients. V. Compare patient-reported functional status and convenience of therapy in patients treated with these regimens.. VI. Correlate germline polymorphisms of DNA repair (e.g., ERCC-1, XRCC1, GST-P1, XPD, and ribonucleotide reductase), target enzymes (e.g., thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase), angiogenesis (e.g., vascular endothelial growth factor), and growth factors (e.g., epithelial growth factor receptor) with survival, progression-free survival, and ...

OBJECTIVES:. I. Determine the safety of gefitinib, fluorouracil, leucovorin calcium, and irinotecan in patients with advanced or recurrent colorectal cancer.. II. Determine the major side effects of this regimen in these patients. III. Determine the response rate, progression-free survival, and overall survival of patients treated with this regimen.. IV. Correlate response and other measures of outcome with epidermal growth factor receptor expression and the expression of genes that impact upon pathways of fluoropyrimidine cytotoxicity in patients treated with this regimen.. OUTLINE: This is a non-randomized, open-label, multi-center study.. Patients receive oral gefitinib daily beginning on day 1, irinotecan IV over 90 minutes on days 1 and 15, and leucovorin calcium IV over 2 hours and fluorouracil IV over 3-5 seconds followed by a 22-hour infusion on days 1, 2, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. ...

TY - JOUR. T1 - Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer. AU - Dócs, Ottó. AU - Fazakas, Ferenc. AU - Horváth, Nóra Lugosiné. AU - Tóth, L.. AU - András, C.. AU - Horváth, Z.. AU - Méhes, G.. PY - 2014/9/24. Y1 - 2014/9/24. N2 - Colorectal cancer (CRC) is a heterogeneous disease presenting with a wide spectrum of morphological and molecular characteristics sometimes even within the same patient. To understand the mechanisms of oscillations in the KRAS status we evaluated the collective of CRC patients tested using allele-specific PCR and Sanger-sequencing. Mutant KRAS allele was observed in 43.3 % of cases. Repeated analysis of KRAS status in recurrent tumors or metastases was performed in 18/665 cases and a total of 6 cases with different KRAS status was found. In three cases the histological pattern of the tumor was identical. In one patient different histology and molecular status was seen between the primary and the recurrent tumor samples. ...

Obesity is associated with an increased risk of breast cancer recurrence and cancer death. Recurrent cancers arise from the pool of residual tumor cells, or minimal residual disease (MRD), that survives primary treatment and persists in the host. Whether the association of obesity with recurrence risk is causal is unknown, and the impact of obesity on MRD and breast cancer recurrence has not been reported in humans or in animal models. Doxycycline-inducible primary mammary tumors were generated in intact MMTV-rtTA;TetO-HER2/neu (MTB/TAN) mice or orthotopic recipients fed a high-fat diet (HFD; 60% kcal from fat) or a control low-fat diet (LFD; 10% kcal from fat). Following oncogene downregulation and tumor regression, mice were followed for clinical recurrence. Body weight was measured twice weekly and used to segregate HFD mice into obese (i.e., responders) and lean (i.e., nonresponders) study arms, and obesity was correlated with body fat percentage, glucose tolerance (measured using intraperitoneal

The purpose of this study is to determine the activity of SCH 717454 in patients with relapsed or recurrent colorectal cancer.

Of the 449 patients who received neoadjuvant chemotherapy, 98 underwent breast-conserving surgery. The average diameter of the tumors was 5.3 cm, and 87.2% reached a size of up to 3 cm. Moreover, 86.7% were classified as clinical stage III, 74.5% had T3-T4 tumors, 80.5% had N1-N2 axilla, and 89.8% had invasive ductal carcinoma. A pathologic complete response was observed in 27.6% of the tumors, and 100.0% of samples had free margins. The 5-year actuarial overall survival rate was 81.2%, and the mean follow-up was 72.8 months. The rates of ipsilateral breast tumor recurrence and locoregional recurrence were 11.2% and 15.3%, respectively. Multifocal morphology response was the only factor related to ipsilateral breast tumor recurrence disease-free survival ...

The prognostic role of positive circumferential resection margins after curative intent surgery for locally advanced esophageal adenocarcinoma

The management of rectal cancer has changed in many countries over the last two decades and resulted in improved survival for the majority of rectal cancer patients. In this thesis some surgical strategies and histopathological aspects to improve and clarify the management of rectal cancer patients are investigated.. Even in the era of TME surgery and radiotherapy, a higher local recurrence rate and shorter survival for rectal cancer patients operated with abdominoperineal resection is reported. In the first paper we describe a new strategy with partial anterior en bloc resection of either the prostate or the vagina, resulting in very low local recurrence rates and excellent long-term survival. Histopathological examination of the specimen lays the foundation for decision making on oncological therapy. A positive circumferential resection margin (CRM) has, in previous papers, been related to a high risk of local recurrence. In the second paper we show that a CRM ≤ 1 mm was not correlated with ...

BACKGROUND: In breast cancer patients (≥70 years), tumour resection plus tamoxifen (T + T) has a higher loco-regional relapse (LR) rate than mastectomy. This study examines factors influencing local recurrence in these cases. METHODS: Clinical records of 71 patients aged ≥70 years, randomised to the T + T arm of 2 randomised trials were reviewed. Cox Proportional Hazards model was used to determine the most significant variables. RESULTS: After 15-years follow-up, LR relapse occurred in 29/71, of whom 5 had synchronous metastatic disease. Most tumours recurred in the index quadrant. Subsequently 21/24 patients with loco-regional recurrence only had salvage mastectomy. Three variables significantly predicted LR: lympho-vascular invasion (LVI) (HR [95% CI]: 11.18 [4.47, 27.95], p | 0.01), ER negative status (HR [95% CI]: 0.27 [0.10, 0.72] p = 0.01), and tumour necrosis (HR [95% CI]: 2.65 [1.10, 6.37], p = 0.03). Final margin status was not associated with LR. CONCLUSIONS: Tumour resection + Tamoxifen

Statins and risk of breast cancer recurrence Minas Sakellakis,1 Karolina Akinosoglou,1 Anastasia Kostaki,2 Despina Spyropoulou,1 Angelos Koutras,1 1Department of Medicine, Division of Oncology, University Hospital, Patras Medical School, Patras, 2Department of Statistics, Athens University of Economics and Business, Athens, Greece Background: The primary end point of our study was to test whether the concurrent use of a statin is related to a lower risk of recurrence and increased relapse-free survival in patients with early breast cancer. Materials and methods: We reviewed 610 female patients with stage I, II, or III breast cancer who had been surgically treated and who had subsequently received at least adjuvant chemotherapy in order to prevent recurrence. Results: Among the 610 patients with breast cancer, 83 (13.6%) were receiving a statin on a chronic basis for other medical purposes. Overall, statin users displayed longer mean relapse-free survival (16.6 vs 10.2 years, P=0.028). After data had

Read Erratum to: Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review, World Journal of Urology on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.

Six modern, prospective, randomized trials have demonstrated that breast-conserving therapy (lumpectomy followed by radiation) offers survival rates equivalent to mastectomy (Table 61-1)1-7; however, when negative margins are not achieved or when radiation therapy is not pursued, breast conservation is associated with higher rates of local recurrence (Tables 61-1 and 61-2).1,2,8-14 Until recently, the impact of local recurrence on survival remained unclear. In 2005, the Early Breast Cancer Trialists Collaborative Group (EBCTCG) published the results of a large meta-analysis combining all individual patient data for 42,080 women who collectively took part in 78 treatment comparisons (more vs less surgery, more surgery vs radiotherapy, radiotherapy vs none) to determine the impact of local recurrence on survival. Specifically, among 10 breast-conservation trials included in the EBCTCG analysis (7311 women), postoperative radiation treatment (XRT) was associated with a statistically significant ...

TY - JOUR. T1 - Predicting the risk of locoregional recurrence after early breast cancer. T2 - an external validation of the Dutch INFLUENCE-nomogram with clinical cancer registry data from Germany. AU - Voelkel, Vinzenz. AU - Draeger, Teresa Maria Cornelia. AU - Oudshoorn, C. AU - de Munck, Linda. AU - Hueting, Tom. AU - Gerken, Michael. AU - Klinkhammer-Schalke, Monika. AU - Lavric, Miha AU - Siesling, Sabine N1 - Springer deal. PY - 2019/7/1. Y1 - 2019/7/1. N2 - Purpose: Follow-up after breast cancer treatment aims for an early detection of locoregional breast cancer recurrences (LRR) to improve the patients outcome. By estimating individuals 5-year recurrence-risks, the Dutch INFLUENCE-nomogram can assist health professionals and patients in developing personalized risk-based follow-up pathways. The objective of this study is to validate the prediction tool on non-Dutch patients. Material and methods: Data for this external validation derive from a large clinical cancer registry in ...

The present invention relates to a scoring system for the prediction of cancer recurrence. More particularly, the present invention concerns with the selection of genes and/or proteins, and generation of formulae with the selected genes and/or proteins for the prediction of cancer recurrence by measuring the expression of genes and/or proteins of human tumor tissues, and comparing their patterns with those of the gene and/or protein expression of human primary tumors from patients who have cancer recurrence and those who do not have cancer recurrence. The present invention also relates to a kit for performing the method of the present invention comprising DNA chip, oligonucleotide chip, protein chip, peptides, antibodies, probes and primers that are necessary for effecting DNA microarrays, oligonucleotide microarrays, protein arrays, northern blotting, in situ hybridization, RNase protection assays, western blotting, ELISA assays, reverse transcription polymerase-chain reaction (hereinafter referred to

With the increasing incidence of ESCC in Asia, it has been reported that the recurrence rate of patients with ESCC following surgery ranges from 36.1% to 64.2%.[6, 20, 21]. Overall survival rates at 2 and 5 years are 22% and 11%, respectively, with a median survival time of only 7 months[16, 17]. Locoregional recurrence after curative esophagectomy in patients with esophageal cancer remains a challenge to clinical oncologists, regardless of the pathological type. The National Comprehensive Cancer Network (NCCN) guidelines indicate that a subgroup of patients with postoperative locoregional recurrence may be able to tolerate concurrent radiochemotherapy[9, 16, 26]. The limited survival benefit may arise from the limited competence of the routine radiation technique. With the disadvantage of localization using 2-dimensional radiation fields, the radiation doses for the targeted tumor in patients with locoregional recurrent ESCC could not satisfy the demands of the prescribed doses. Curative ...

As mentioned, one of the most important partners in allowing or preventing metastatic cell survival and growth is immune cancer surveillance [20]. If immune surveillance and its proper balance are key to prevent or fight against an effective metastatic process, it is likely that disruption of the immune surveillance system plays a key role in the recognition of HCC recurrence. Immune surveillance is the result of several factors that are the consequence of the relationship between the personal inflammatory/immune phenotype and the modification of the inflammation process that is in place during viral infection and its modification by effective therapy. Thus, inflammatory status with heterogeneous activation of stromal cells and lymphocyte recruitment is sure responsible for the delay, or even complete abrogation, of the growth of clones of cells that may have nested away from the primary tumor. In the setting of DAA-based antiviral therapy, there is an extremely fast inhibition of HCV ...

Local recurrence is a major cause of morbidity and mortality, usually implies a worse prognosis. It may occur as a result from two potential etiopathogeneses. First, metastases through endothelial-lined channels occur to both lymphatic and hematogenous routes [18], which are controlled by neoadjuvant therapy and optimal TME. Indeed, TME reduced the high local recurrence rates from 30-40% to 5-10% [19] and even greater when associated with chemoradiotherapy (CRT) [20]. The second is by implantation of viable exfoliated malignant cells from a rectal adenocarcinoma on preexisting benign perineal lesions [21-24]; it was estimated that 70% of the specimens were found to have viable exfoliated colorectal cancer cells with median cell number ranging from 0.55 × 105 to 0.78 × 10 [6].. Since the first case of cell implantation into the anal fistula in 1954 by Guiss [4], several case reports and small case series reported the colorectal cancer recurrence on preexisting benign perineal lesions such as ...

and LinkedIn.. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the Oncotype DX Breast Recurrence Score test to physicians, patients and payors; the results of the TAILORx study including its implications on clinical treatment decisions; the ability of the Oncotype DX Breast Recurrence Score test to improve patient outcomes; and the ability of the company to expand commercial access and increase utilization of its Oncotype DX Breast Recurrence Score test. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the results of clinical studies; the applicability of clinical study results to actual outcomes; the ability of the test results to change treatment ...

Despite improvements in adjuvant therapy, late systemic recurrences remain a lethal consequence of both early- and late-stage breast cancer. A delayed recurrence is thought to arise from a state of tumor dormancy, but the mechanisms that govern tumor dormancy remain poorly understood. To address the features of breast tumors associated with late recurrence, but not confounded by variations in systemic treatment, we compiled breast tumor gene expression data from 4,767 patients and established a discovery cohort consisting of 743 lymph node-negative patients who did not receive systemic neoadjuvant or adjuvant therapy. We interrogated the gene expression profiles of the 743 tumors and identified gene expression patterns that were associated with early and late disease recurrence among these patients. We applied this classification to a subset of 46 patients for whom expression data from microdissected tumor epithelium and stroma was available, and identified a distinct gene signature in the stroma and

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial t

True or False. A positive margin which is defined as ink on ductal carcinoma in situ (DCIS) is associated with an increase in ipsilateral breast tumor recurrence (IBTR), which is nullified by the use of whole-breast radiation therapy (WBRT). ...

See also bug #70693 Activesyncd is losing the nth attribute for monthly repeating BYDAY events. The following EAS data: ,Recurrence xmlns=Calendar:, ,Recurrence_Type,3,/Recurrence_Type, ,Recurrence_Interval,1,/Recurrence_Interval, ,Recurrence_WeekOfMonth,1,/Recurrence_WeekOfMonth, ,Recurrence_DayOfWeek,16,/Recurrence_DayOfWeek, ,/Recurrence, is turned into the following RRULE: RRULE:FREQ=MONTHLY;BYDAY=TH which should be: RRULE:FREQ=MONTHLY;BYDAY=1TH This is obviously related to bug #70693. Until I investigate further, I dont know if this is caused by the same underlying problem as that bug, is a deliberate attempt to avoid triggering that bug or is a separate bug. Even if this is separate, bug #70693 may still prevent the corrected event from being synchronised. As events with recurrence like first Monday of the month are very common, it would be nice to fix this ...

Treatment of recurrent breast cancer depends mainly on where the cancer recurs and past treatment. Learn about treatment of local or metastatic recurrence.

Treatment of recurrent breast cancer depends mainly on where the cancer recurs and past treatment. Learn about treatment of local or metastatic recurrence.

Approximately 10% to 15% of patients with stage I/II invasive breast cancer will develop a clinically isolated local recurrence. The standard management of an ipsilateral breast tumor recurrence following breast- ...

Eliminating pro-inflammatory cells after treatment relieves symptoms in mice.. January 17, 2017/Novato, California: Standard chemotherapy is a blunt force instrument against cancer - and its a rare cancer patient who escapes debilitating side effects from systemic treatments that mostly affect dividing cells, both malignant and healthy, throughout the body. Researchers at the Buck Institute and elsewhere now show that chemotherapy triggers a pro-inflammatory stress response termed cellular senescence, promoting the adverse effects of chemotherapy as well as cancer relapse and metastasis. Eliminating the senescent cells in mice prevented the side effects and relapse. The research is published in Cancer Discovery.. While chemotherapy does save lives, it often comes with a very high price, said Judith Campisi, PhD, Buck faculty and senior scientist on the study. Our work in mice studied the effects of chemotherapy on cancer relapse and other serious side effects. It provides a ...

We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...

TY - JOUR. T1 - Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer. T2 - A case-control study. AU - Haffty, Bruce G.. AU - Brown, Felix. AU - Carter, Darryl. AU - Flynn, Stuart. PY - 1996/7/1. Y1 - 1996/7/1. N2 - Purpose: The purpose of this study is to determine the prognostic significance of overexpression of the HER-2 neu oncoprotein with respect to local relapse following conservative surgery and radiation therapy (CS+RT). Methods and Materials: Twenty consecutive patients who sustained a local recurrence as the first and only site of failure following CS+RT comprised the case population base for this study. Only patients who received no adjuvant systemic chemotherapy or tamoxifen were selected for analysis. Following the identification of 20 consecutive local-relapse patients, the patient database was searched for 20 matching control patients who did not sustain a local relapse. Each control patient was ...

Optimizing the odds of avoiding cancer recurrence: Go jogging in your Speedo or bikini!. I have been looking around, mostly on pubmed ( https://www.ncbi.nlm.nih.gov/pubmed/ ), for non-chemotherapy strategies to reduce cancer recurrence and mortality. To avoid an overlong post, I will summarize very briefly the information I have found, with hopefully a link to one supporting study. If the topic interests you, I encourage you to go to pubmed and read more. Of course, all of this information is from my perspective only and you should use it as a springboard for discussion with your doctor or your own research.. Vitamin D: One of the most surprising results of my research was the impact of vitamin D on colorectal cancer recurrence and mortality. One article reports, Freedman et al demonstrated in one of the largest prospective studies including 16,818 participants that CRC mortality was inversely related to serum 25(OH)D level. Individuals with serum levels of 50-80 ng/mL and , 80 ng/mL had a ...

While we do not talk about recurrence much in my family, everyone knows way too much about it because we all remember my mothers experience. She was diagnosed at an early stage. Low grade. Her cancer still metastasized.. Broadly speaking, the greatest risk of recurrence is during the first two years following diagnosis. Certain more aggressive breast cancers are more likely to metastasize early on, before the five year benchmark. Others, like my mothers and mine (ER+,PR+), are less likely to metastasize early on, but can and sometimes do many years later. A reader (thank you) shared this piece, Understanding the Risk of Late Recurrence of Breast Cancer.. The bottom line is, theres no guarantee. The five-year benchmark suggesting youre cured is a myth that has been perpetuated for years partly due to Pink Ribbon Fantasy Land hype.. Many women (and men) do struggle with recurrence worries.. Perhaps adding to this worry (for me anyway and perhaps for you, too) is the fact that generally ...

Eighty-five patients met the inclusion criteria, and 27% of them had an atypical histology. Typical EVNs had a better prognosis than atypical EVNs after primary treatment, with a 5-year recurrence rate of 36% compared with 68% (p , 0.001), and a 5-year mortality rate of 4% compared with 44%, respectively (p , 0.001). Age younger 50 years was associated with a better prognosis than age equal to or greater than 50 years, with a 5-year recurrence rate of 33% and 74%, respectively (p , 0.001), and a 5-year mortality rate of 4% and 52%, respectively (p , 0.001). Multivariate analysis demonstrated that atypical EVNs carried significantly increased risk for recurrence (hazard ratio [HR] 4.91, p , 0.001) and death (HR 22.91, p , 0.01). Gross-total resection was superior to subtotal resection (STR) alone in tumor control rates for typical EVNs (95% and 68%, p , 0.05), and there was a trend for adjuvant external-beam radiotherapy to benefit STR. There was suggestion of similar trends in patients with ...

Immunotherapy (tumor vaccine) is recommended for dogs with malignant melanoma because of the high risk of metastasis to the lymph nodes and lungs. Chemotherapy is recommended for dogs with oral osteosarcoma. Chemotherapy should also be considered for other oral tumors and the palliative management of cats with SCC.. PROGNOSIS. Dogs. Malignant Melanoma. Malignant melenoma is the most common oral tumor in dogs and also has the highest metastatic potential, particularly to the regional lymph nodes and lungs. Based on a combination of early papers, the local recurrence rate following mandibulectomy was 22% with a median survival time of 9-11 months and a 1-year survival rate of 21%. Similarly, the local recurrence rate following maxillectomy is as high as 48% with a median survival time of 5-10 months and a 1-year survival rate of 27%. However, in two large 2014 studies, the overall local recurrence rate was 16%-17%. Clinical stage has prognostic significance with median survival times of 20 months ...

There has been scanty data regarding the clinical significance of tumor conspicuity in pancreatic cancer. In this study, we attempted to investigate the prognostic significance of pancreatic tumor conspicuity and determine prognostic factors for postoperative recurrence in patients with surgically resected pancreatic cancer. Between January 2011 and September 2019, 62 patients who underwent preoperative computed tomography (CT) for pancreatic cancer were retrospectively included. Two reviewers evaluated various clinical, imaging, and pathologic variables and reviewed all available medical records to determine patient outcomes after surgery. Tumor conspicuity was defined as the attenuation ratio between normal parenchyma and tumor lesions on dynamic-enhanced CT images and represented the conspicuity score. Recurrence-free survival and overall survival were investigated using Cox regression analysis. Patient mean age was 65.9 (±11.6) years, and 56.5% were male. The median follow-up period was 11 months

Recurrent Breast cancer can return after successful treatment. The initial treatment involves eliminating all cancer cells, but it is possible for a few to

Although the initial cancer treatment is aimed at eliminating all cancer cells, a few of them may still stay in the body, which likely cause breast cancer recurrence. Breast cancer can recur at any time but mostly occur in the first three to five year

The main objective of the current investigation was to study the efficacy of EPA as an inhibitor of recurrent colorectal cancer growth and to determine whether EPA in combination with FuOx would be more effective than either agent/regimen alone.. The preventive and therapeutic efficacy of a combination of EPA and DHA or each PUFA alone has been demonstrated in multiple preclinical studies using a variety of rodent models of early-stage colorectal cancer (37). These studies have consistently demonstrated reduction in colorectal cancer incidence (reviewed in ref. 37). Our data demonstrate for the first time that EPA acts synergistically with FuOx to markedly inhibit the growth of chemoresistant colon cancer cells that form bulk of the recurrent tumor. Although the underlying cause for tumor recurrence is not fully understood, one of the reasons is thought to be the presence of CSCs/CSLCs that are resistant to conventional chemotherapy and retain limitless potential to regenerate (1-3, 38). The ...

Process monitoring is an important research problem in numerous areas. This paper proposes a novel process monitoring scheme by integrating the recurrence plot (RP) method and the control chart technique. Recently, the RP method has emerged as an effective tool to analyze waveform signals. However, unlike the existing RP methods that employ recurrence quantification analysis (RQA) to quantify the recurrence plot by a few summary statistics; we propose new concepts of template recurrence plots and continuous-scale recurrence plots to characterize the waveform signals. A new feature extraction method is developed based on continuous-scale recurrence plot. Then, a monitoring statistic based on the top- approach is constructed from the continuous-scale recurrence plot. Finally, a bootstrap control chart is built to detect the signal changes based on the constructed monitoring statistics. The comprehensive simulation studies show that the proposed

For treatment, most women with newly diagnosed ovarian cancer undergo surgery to remove as much of the visible tumor as possible and determine a specific diagnosis. Survival time is markedly better for women who have complete tumor removal, yet great variability exists in the extent of tumor removal. For women in whom an optimal removal is not feasible, or who are unable to undergo surgery, neoadjuvant chemotherapy can reduce tumor size and facilitate subsequent surgical resection. While the majority of women respond well to initial treatments, most will experience a recurrence of ovarian cancer, and virtually all recurrent ovarian cancers ultimately become resistant to current drug therapies. The committee said there is a need for better tools to predict near- and long-term response to treatments for both newly diagnosed and recurrent cancers.. While clinicians should have better ways to select the most appropriate treatment for individual patients, they also require more treatment options, and ...

Weill Cornell Medicine is one of only a handful of locations in the United States enrolling patients in this innovative trial for GBM

Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes the genetic mutation screening multicenter study that he was the lead author for and presented at the 2011 annual meeting of the American Society of Clinical Oncology.

Portrait of Mark Ptashne (born 1940), US molecular biologist. Ptashne was the first scientist to demonstrate specific binding between protein and DNA. Much of his research has focused on molecular mechanisms in the lifecycle of the virus bacteriophage lambda. He holds the Ludwig Chair of Molecular Biology at Memorial Sloan-Kettering Cancer Center in New York, where he works on gene regulation mechanisms in yeast. - Stock Image C021/9054

CVSROOT: /cvs/purrs Module name: purrs Changes by: zolo at cs.unipr.it 2003-11-14 12:45:47 Modified files: demos : purrs_rrs_cgi.cc src : Recurrence.cc Recurrence.defs.hh Recurrence.inlines.hh rr_classifier.cc tests : rrs_driver.cc Log message: Removed the status `HAS_HUGE_DECREMENT from `Solver_Status. Now the status `HAS_HUGE_DECREMENT of `Classifier_Status is mapped in the status `TOO_COMPLEX of `Solver_Status. Added and fixed several comments. Patches: http://www.cs.unipr.it/cgi-bin/cvsweb.cgi/purrs/demos/purrs_rrs_cgi.cc.diff?cvsroot=purrs&r1=1.24&r2=1.25 http://www.cs.unipr.it/cgi-bin/cvsweb.cgi/purrs/src/Recurrence.cc.diff?cvsroot=purrs&r1=1.121&r2=1.122 http://www.cs.unipr.it/cgi-bin/cvsweb.cgi/purrs/src/Recurrence.defs.hh.diff?cvsroot=purrs&r1=1.126&r2=1.127 http://www.cs.unipr.it/cgi-bin/cvsweb.cgi/purrs/src/Recurrence.inlines.hh.diff?cvsroot=purrs&r1=1.88&r2=1.89 http://www.cs.unipr.it/cgi-bin/cvsweb.cgi/purrs/src/rr_classifier.cc.diff?cvsroot=purrs&r1=1.75&r2=1.76 ...

Robertson , C , Ragupathy , S K A , Boachie , C , Fraser , C , Heys , S D , Maclennan , G , Mowatt , G , Thomas , R E , Gilbert , F J & Mammographic Surveillance Health Technology Assessment Group 2011 , Surveillance mammography for detecting ipsilateral breast tumour recurrence and metachronous contralateral breast cancer : a systematic review , European Radiology , vol. 21 , no. 12 , pp. 2484-2491 . https://doi.org/10.1007/s00330-011-2226- ...

Recurrent squamous cell carcinoma of the skin treated successfully with single agent cetuximab therapy Selcuk Seber,1 Aylin Gonultas,2 Ozlem Ozturk,2 Tarkan Yetisyigit1 1Department of Medical Oncology, Faculty of Medicine, Namik Kemal University, 2Pathology Department, Tekirdag State Hospital, Tekirdag, Turkey Abstract: Recurrent squamous cell carcinoma of the skin is a rare but difficult to treat condition. Frequently, the disease presents itself in elderly patients with poor performance status and bearing many comorbidities, thus the decision to administer systemic chemotherapy becomes difficult to make. In addition, current chemotherapeutic protocols response rates are far from satisfactory. Recently cetuximab, a chimeric antibody against epidermal growth factor receptor, is increasingly being reported as an alternative treatment. We therefore report this case of a recurrent squamous cell carcinoma of the skin in an elderly woman with poor performance status and who had an excellent clinical

TY - JOUR. T1 - Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix. T2 - A New York Gynecologic Oncology Group study. AU - Nezhat, Farr. AU - Wadler, Scott. AU - Muggia, Franco. AU - Mandeli, John. AU - Goldberg, Gary. AU - Rahaman, Jamal. AU - Runowicz, Carolyn. AU - Murgo, Anthony J.. AU - Gardner, Ginger J.. N1 - Funding Information: Supported by N01-CM-07003 from the National Cancer Institute, NIH. Previously presented in part at the American Society of Clinical Oncology, May 2002. Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2004/4. Y1 - 2004/4. N2 - Objective. Bryostatin-1 is a macrocyclic lactone that has been shown to regulate protein kinase C (PKC) activity and thereby potentially inhibit tumor invasion, angiogenesis, cell adhesion, and multidrug resistance. In preclinical experiments, bryostatin-1 induces tumor growth inhibition and enhances cytotoxicity when combined with other agents including ...

TY - JOUR. T1 - Diagnosis of recurrent brain tumor. T2 - Value of 201TI SPECT vs 18F- fluorodeoxyglucose PET. AU - Kahn, D.. AU - Follett, K. A.. AU - Bushnell, D. L.. AU - Nathan, M. A.. AU - Piper, J. G.. AU - Madsen, M.. AU - Kirchner, P. T.. PY - 1994. Y1 - 1994. N2 - OBJECTIVE. This prospective study was designed to compare the sensitivity and specificity of a relatively simple examination, 201TI chloride single- photon emission CT (SPECT), with a more complex examination, 18F- fluorodeoxyglucose (FDG) positron emission tomography (PET), in patients thought to have recurrent brain tumor. Because both agents have been shown to be markers of viable tumor, we hypothesized that their sensitivity and specificity should be the same. SUBJECTS AND METHODS. Nineteen patients with evidence of recurrent tumor on CT or MR images were studied with both 201TI SPECT and FDG PET imaging. Two patients were examined twice, so a total of 21 studies were evaluated. The 201TI SPECT and FDG PET examinations were ...

We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with advanced, persistent or recurrent endometrial carcinoma. We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51 patients with advanced (FIGO stage III-IV) or relapsed endometrioid endometrial cancer. Patients were stratified into subsets of estrogen receptor (ER) positive and ER negative patients. Recruitment to the ER negative group was stopped prematurely after 12 patients due to slow accrual. In the ER positive patients, we observed an overall response rate of 10%, and a lack of progression after 6 months in 35% of the patients. No responses were registered in the ER negative patients, and all had progressive disease within 6 months. For the total group of patients, the median progression free survival (PFS) was 3.1 months (95% CI: 2.0-4.1). In the ER positive patients the median PFS was 3.8 months (95% CI: 0.7-6.9) and in the ER negative patients it was 2.6 months (95%

(PRN) Quest Diagnostics Launches Test to Help Oncologists Predict Risk of Breast Cancer Recurrence in Women with Estrogen Receptor (ER)-Positive, Lymph Node- Negative Cancers IL17BR, to help physicians predict the risk of disease recurrence in women with estrogen receptor (ER)-positive, lymph node-negative breast cancer. Quest Diagnostics is the first company to develop a breast cancer recurrence test based on licensed gene-expression profiling technology from AviaraDx Inc., a molecular cancer profiling company located in Carlsbad, California. Launched at the San Antonio Breast Cancer Symposium, December 14 - 17, 2006, the Breast Cancer Gene Expression Ratio is based on the ratio of the expression of two genes: the homeobox gene-B13 (HOXB13) and the interleukin- 17B receptor gene (IL17BR). The clinical value of the Breast Cancer Gene Expression Ratio also is supported by a study published earlier this year in Clinical Cancer Research(2). According to the American Cancer Society (ACS), more than 210

PROGNOSIS. Dogs. The prognosis for dogs with pelvic tumors depends on the diagnosis. Local tumor recurrence was reported in 22.9% of 83 dogs treated with hemipelvectomy in one study, and the median time to local recurrence was 257 days. There was no association of local tumor recurrence with either completeness of excision or tumor type, but local recurrence was associated with a significantly increased risk of tumor-related death (3.8-times greater risk than dogs without local recurrence). Distant metastasis was reported in 44.6% of dogs with a median time to metastasis of 248 days. Four dogs with infiltrative lipomas were cured with hemipelvectomy. For six dogs with hemangiosarcoma, the metastatic rate was 83%, the mean survival time was 179 days, and the 1- and 2-year survival rates of 33% and 0%, respectively. For 34 dogs with soft tissue sarcomas, the local recurrence rate was 15%, the metastatic rate was 26%, the mean survival time was 373 days, and the 1- and 2-year survival rates were ...

Giving chemotherapy drugs every 2 weeks instead of the usual every 3 weeks reduces the risk of breast cancer recurrence and death, according to research published in The Lancet on 7 February 2019.. The study, undertaken by the Early Breast Cancer Trialists Collaborative Group (EBCTCG) analysed data from over 37,000 women with early (operable) breast cancer who had taken part in 26 randomised trials from across the world that compared dose-intense chemotherapy with standard schedule chemotherapy.. The analysis aimed to find out whether increasing the dose intensity of chemotherapy (the amount of drug delivered per unit time), was more effective at lowering breast cancer recurrence and death rates than standard schedule chemotherapy regimens. One way to increase dose intensity was to use the same chemotherapy agents at the same doses but administer treatment every two weeks instead of every three weeks. The average weekly dose is therefore 50% higher with 2-weekly treatment than with the ...

On Tuesday, August 1, 2017, I received my third dose of chemotherapy. Everything went well and the next day I was feeling excellent, although some of that can be contributed to the steroid pre-medication. As an added plus, I was looking forward to having family in town for the weekend. Life seemed pretty good.. In the back of my mind, I knew that I likely hadnt reached the nadir, or lowest point, in my blood counts from the prior chemotherapy. As such, there was a possibility that I might not be feeling 100% for my visitors.. Sure enough, by Wednesday evening I started running a mild temperature. No big deal - it was below the 38 degrees Celsius (°C) cutoff for an official temperature. On Thursday I wasnt feeling energetic and napped most of the day. Then the real fun started.. My temperature rose Thursday evening and the physician-on-call at Memorial Sloan-Kettering Cancer Center (MSKCC) recommended that I come to urgent care to get things checked out. So, Lorie and I made the drive from ...

The authors report a case of prostate cancer recurrence in the bladder wall after radical prostatectomy studied by magnetic resonance imaging with diffusion weighted and dynamic contrast-enhanced sequences.

Purpose: To review the risk of local recurrence and impact of salvage therapy after Watch and Wait for rectal cancer with complete clinical response (cCR) after chemoradiation therapy (CRT). Methods and Materials: Patients with cT2-4N0-2M0 distal rectal cancer treated with CRT (50.4-54 Gy + 5-fluorouracil-based chemotherapy) and cCR at 8 weeks were included. Patients with cCR were enrolled in a strict follow-up program with no immediate surgery (Watch and Wait). Local recurrence-free survival was compared while taking into account Watch and Wait strategy alone and Watch and Wait plus salvage. Results: 90 of 183 patients experienced cCR at initial assessment after CRT (49%). When early tumor regrowths (up to and including the initial 12 months of follow-up) and late recurrences were considered together, 28 patients (31%) experienced local recurrence (median follow-up time, 60 months). Of those, 26 patients underwent salvage therapy, and 2 patients were not amenable to salvage. In 4 patients, ...

Background. In recent years there has been a dramatic increase in the use of breast conservation therapy for patients with cancer. There are several factors associated with local recurrence but none are considered absolute contraindication for breast conserving therapy except multifocal carcinoma. This single-institution series investigates the effects of multiple factors on local relapse-free survival after breast-conserving therapy for women with invasive cancer. Methods. One-hundred and ninety-two patients (193 cancers) with invasive carcinoma underwent breast-conserving therapy (surgery, radiation therapy and chemotherapy if indicated) at University of Alabama at Birmingham Hospital from 1986 through 1995. The Kaplan-Meier method was used to calculate curves for local recurrence. The log rank statistic test was used for statistical comparison between curves. The Cox proportional hazards model was used for multivariate analysis. Significance was defined as p < 0.05. Results. Mean patient age ...

Prostate Cancer recurrence simply implies that initial treatment administered to treat prostate cancer was ineffective in eliminating it. There are still...

Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme This study is currently recruiting participants. Verified July 2012 by…

TY - JOUR. T1 - Prevention of bladder cancer recurrence by retinoic acid-ketoconazole. T2 - A promising strategy?. AU - Lotan, Yair. AU - Lotan, Reuben. PY - 2008/1. Y1 - 2008/1. KW - Bladder cancer. KW - Ketoconazole. KW - Prevention. KW - Retinoic acid. KW - Schistosomiasis. UR - http://www.scopus.com/inward/record.url?scp=42549124669&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=42549124669&partnerID=8YFLogxK. U2 - 10.4161/cbt.7.1.5860. DO - 10.4161/cbt.7.1.5860. M3 - Comment/debate. C2 - 18347420. AN - SCOPUS:42549124669. VL - 7. SP - 101. EP - 102. JO - Cancer Biology and Therapy. JF - Cancer Biology and Therapy. SN - 1538-4047. IS - 1. ER - ...

In the last decades, several gene expression-based predictors of clinical behavior were developed for breast cancer. A common feature of these is the use of multiple genes to predict hormone receptor status and the probability of tumor recurrence, survival or response to chemotherapy. We developed an online analysis tool to compute ER and HER2 status, Oncotype DX 21-gene recurrence score and an independent recurrence risk classification using gene expression data obtained by interrogation of Affymetrix microarray profiles. We implemented rigorous quality control algorithms to promptly exclude any biases related to sample processing, hybridization and scanning. After uploading the raw microarray data, the system performs the complete evaluation automatically and provides a report summarizing the results. The system is accessible online at http://www.recurrenceonline.com . We validated the system using data from 2,472 publicly available microarrays. The validation of the prediction of the 21-gene ...

Invasive ductal carcinoma is the most common type of breast malignancy, with varying molecular features and resistance to treatment. Although CD44+/CD24- cells are believed to act as breast cancer stem cells and to be linked to poor prognosis in some patients, the association between these cells and tumor recurrence or metastasis in all or some types of invasive ductal carcinoma is unclear. A total of 147 randomly selected primary and secondary invasive ductal carcinoma samples were assayed for expression of CD44, CD24, ER, PR, and Her2. The association between the proportions of CD44+/CD24- tumor cells and the clinico-pathological features of these patients was evaluated. CD44+/CD24- tumor cells were detected in 70.1% of the tumors, with a median proportion of 5.8%. The proportion of CD44+/CD24- tumor cells was significantly associated with lymph node involvement (P = 0.026) and PR status (P = 0.038), and was correlated with strong PR status in patients with recurrent or metastatic tumors (P = 0.046)

In a multicentre, double-blind, randomised, placebo-controlled study (MA-17), over 5,100 postmenopausal women with receptor-positive or unknown primary breast cancer who had completed adjuvant treatment with tamoxifen (4.5 to 6 years) were randomised to either letrozole or placebo for 5 years. The primary endpoint was disease-free survival, defined as the interval between randomisation and the earliest occurrence of loco-regional recurrence, distant metastasis, or contralateral breast cancer. The first planned interim analysis at a median follow-up of around 28 months (25% of patients being followed up for at least 38 months), showed that letrozole significantly reduced the risk of breast cancer recurrence by 42% compared with placebo (HR 0.58; 95% CI 0.45, 0.76; P=0.00003). The benefit in favour of letrozole was observed regardless of nodal status. There was no significant difference in overall survival: (letrozole 51 deaths; placebo 62; HR 0.82; 95% CI 0.56, 1.19). Consequently, after the the ...

Clinical trial for Locally Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma , Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Bradmer Pharmaceuticals, Inc. (Bradmer) is requesting approval to study the safety of Neuradiab® when combined with Bevacizumab (Avastin) therapy given at a minimum of 30 days after Neuradiab administration in patients with a first or second recurrence of glioblastoma multiforme (GBM), in an attempt to manage life threatening recurrence of Grade IV malignant glioma.

These results suggest that the impact of postdiagnosis changes in dietary intake on breast cancer recurrence may vary depending on the molecular characteristics of the original tumor. We know of no studies with which to compare our findings.. Our finding that expression of the IGFI receptor was predictive of a poor prognosis is consistent with most published studies (8,19-22), although others concluded that expression of this receptor was a favorable prognostic indicator (23). Published data about associations of IGFI receptor expression with breast cancer clinical characteristics are conflicting (8, 19,21-24).. These data also indicated that African American and Latina postmenopausal breast cancer survivors were more likely to have a primary cancer that was positive for the IGFI receptor, although the sample sizes were small. However, a recently published study of tumor tissue (n = 47) found no difference in IGFI receptor protein expression between non-Hispanic White and African American women ...

Cancer genomic profiling has improved our understanding of the key drivers of tumor development, clonal evolution, and recurrence, and aided precision medicine efforts to eradicate therapy-resistant cancer cell clones. In this issue, You and colleagues report these results for recurrent nasopharyngeal carcinoma, an aggressive malignancy associated with poor outcomes with recurrent disease. They identify a crucial contributory role of clonal NF-κB activating mutations in pathogenesis of recurrence in this cancer and provide a promising target for combinatorial therapeutic approaches.. See related article by You et al., p. 5930 ...

The patients were predominantly men (20/23:87%) between 45-77 years of age. 22 patients were staged as 4a (TNM version 7) and 1 was metastatic at presentation. Excluding the metastatic patient, over half received induction chemotherapy (12/22:55%). The majority received radical chemo-radiotherapy (19/22:86%). Recurrence post treatment occurred between 5-58 months, (median = 14 months). In 10 patients, recurrence was within 12 months, in 12 patients, over 12 months. Site of primary disease or delivery of induction chemotherapy did not influence timing of recurrence. Current smokers were more likely to recur early (,12 months) compared to non-smokers. The most frequent sites of disease recurrence were lung (n=10), bone (n=9), liver (n=6) or within the oropharynx (n=11). In early recurrence, local disease was most prevalent. In later recurrences, bone and lung metastases were most frequently seen. 18/23 (78%) patients died from their disease with a mean time from disease recurrence to death of 9.4 ...

Results An average of 13.8 lymph nodes were removed. 45 patients (57.7%) had a positive lymph node status, with a mean of 3.2 involved nodes per patient. 1, 5 and 10-year OS for N+ status was 60%, 10% and 10%, while N- OS was 82%, 41% and 41% (p=0.000). Similarly, 1, 5 and 10-year DFS was worse in the N+ group (71%, 45% and 42%) compared to N- (91%, 65% and 60%) (p=0.045). There was no difference in 1, 5 and 10-year OS (70%, 23%, 20% vs 70%, 23% and 20%, p=0.690) and DFS (78%, 48% and 48% vs 82%, 58% and 58%, p=0.305) when ,10 nodes were removed (n=39) compared to ≥10 nodes (n=36). There was no difference in 1, 5 and 10-year OS (63%, 9% and 9% vs 60%, 10% and 10%, p=0.562) and DFS (78%, 40% and 40% vs 65%, 46% and 40%, p=0.795) when LNR ,0.25 (n=22) was compared to LNR ,0.25 (n=23). No difference was found when a cut-off of 15 total excised lymphnodes and LNR of 0.50 was used. ...

Current Examinations Let You Know Seeing Prostate Cancer Recurrence. Prostate cancer recurrence is a very rare phenomenon as early perception helps your specialist to select the care pick that offers terminated remedy. On the other entrust, if the disease spreads outside the prostate glands then you will find occasions that repeat might take place. Nevertheless, were not receiving provoke of hysterium as your doctor can heal the reappearance by removing the prostate glands.. Having used to say, youll be able to use the latest preventive measures after the completion of the management to ensure that prostate cancer recurrence should not come about. 1 of all the best techniques of preventing the revert of the disease is to use vaccination. It was probably reverberated odd but the reality is that this inoculation contains substances, which has the capability of breaking down the cancer cells and stopping the recurrence.. Observation shows that the disease reverts within the five years post ...

In patients receiving skin transplantation, 1 case of squamous carcinoma and 1 case of fibrous sarcoma relapsed after 1 year and 2.5 years respectively and were given radical resection and skin flap grafting; in patients receiving skin flap grafting, 1 case of vasculosarcoma and 1 case of squamous carcinoma relapsed after 6 months and 3 months respectively, and gave up treatment; 1 case of fibrous sarcoma relapsed after 2 years and was given radical resection and skin flap grafting ...

A prospective validation study of a 21-gene expression assay showed that treatment with endocrine therapy alone in women with hormone receptor-positive, HER2-negative breast cancer who had a low recurrence risk score resulted in low risk of recurrence. All patients included in the study were eligible for adjuvant chemotherapy on the basis of current guidelines, as reported in The New England Journal of Medicine by Joseph A. Sparano, MD, of Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, and colleagues.1. Study Details. Between April 2006 and October 2010, the trial enrolled 10,253 women with hormone receptor-positive, HER2-negative, axillary node-negative breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6-1.0 cm in the greatest dimension and intermediate or high tumor grade) who met established guidelines for receiving adjuvant chemotherapy.. A 21-gene reverse-transcriptase polymerase chain reaction assay was performed on ...

TY - JOUR. T1 - The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma. AU - Pompucci, Angelo. AU - De Bonis, Pasquale. AU - Anile, Carmelo. AU - Sica, Gigliola. AU - Maira, Giulio. AU - Mangiola, Annunziato. PY - 2013. Y1 - 2013. N2 - Treatment of glioblastoma recurrence can have a palliative aim, after considering risks and potential benefits. The aim of this study is to verify the impact of surgery and of palliative adjuvant treatments on survival after recurrence.. AB - Treatment of glioblastoma recurrence can have a palliative aim, after considering risks and potential benefits. The aim of this study is to verify the impact of surgery and of palliative adjuvant treatments on survival after recurrence.. KW - Adult. KW - Aged. KW - Aged, 80 and over. KW - Brain Neoplasms. KW - Chemoradiotherapy, Adjuvant. KW - Combined Modality Therapy. KW - Confidence Intervals. KW - Data Interpretation, Statistical. KW - Female. KW - Follow-Up Studies. KW - ...

Our desmoid fibromatosis local recurrence nomogram is a tool designed to predict the likelihood of survival without the desmoid tumor returning at the site of initial surgery after the tumor is removed through surgery. The probability of survival free of local recurrence is calculated for three years, five years, and seven years after surgery.

The aim of this study was to identify patient-, tumour- or treatment-related factors associated with young age that might explain the higher risk of ipsilateral breast recurrence that occurs after breast-conserving therapy (BCT) in young breast cancer patients. In the boost versus no boost trial, 5569 early-stage breast cancer patients were entered. All patients underwent

Four candidate genes were differentially expressed in PCa recurrence. Of these, low AXIN2 expression was internally validated in the discovery cohort. Validation in external cohorts and in silico demonstrated that low AXIN2 was independently associated with more aggressive PCa, biochemical recurrence, and metastasis-free survival after RP. Functionally, siRNA-mediated depletion of AXIN2 significantly increased invasiveness, proliferation, and tumor growth. Conversely, ectopic overexpression of AXIN2 significantly reduced invasiveness, proliferation, and tumor growth ...

BACKGROUND: The role of postoperative radiotherapy in pathological T2-3N0M0 esophageal squamous cell carcinoma is unknown. We aimed to evaluate the efficacy and safety of postoperative radiotherapy in patients with pathological T2-3N0M0 thoracic esophageal squamous cell carcinoma. MATERIALS AND METHODS: Patients aged 18-72 years with pathological stage T2-3N0M0 esophageal squamous cell carcinoma after radical surgery and without neoadjuvant therapy were eligible. Patients were randomly assigned to surgery alone or to receive postoperative radiotherapy of 50.4 Gy in supraclavicular field and 56 Gy in mediastinal field in 28 fractions over 6 weeks. The primary endpoint was disease-free survival. The secondary endpoints were local-regional recurrence rate, overall survival, and radiation-related toxicities. RESULTS: From October 2012 to February 2018, 167 patients were enrolled in this study. We analyzed 157 patients whose follow-up time was more than 1 year or who had died. The median follow-up ...

Study examines the impact of cholesterol-lowering medications on breast cancer recurrence for those receiving adjuvant endocrine therapy.

To measure stroke victims self rated health (SRH) status and SRH transition, and to compare how the two are prospectively associated with disability and recurrence free survival. Prospective case registry study with face to face follow up interviews at three months, one, two, and three years. Ascertained were SRH status and SRH transition using single question assessments, Barthel Index (BI), Frenchay Activities Index (FAI), and Mini Mental State Examination (MMSE). A multiethnic inner city population of 234 533. Patients surviving the initial three months after a first in a lifetime stroke in 1995 to 1998. Of 690 stroke survivors 561 (81.3%) could complete the self report items. Answers to the item on SRH status did not vary significantly between the four follow up interviews. However, responses to the item on SRH transition changed significantly during follow up with three months ratings being more negative than all

Aim: Despite advances in rectal cancer treatment, local recurrence (LR) remains a significant problem. To select high-risk patients for different treatment options aimed at reducing LR, it is essential to identify LR risk factors. Method: Local recurrence and survival rates of 4153 patients registered 1995-1997 in the Swedish Rectal Cancer Registry were analysed. LR risk factors were analysed by multivariate methods. For LR patients the registry was validated and additional data retrieved. Results: The 5-year overall and cancer-specific survival rates were 45% and 62% respectively. LR was registered in 326 (8%) patients. After R0-resections for tumours in TNM stages I-III, LR developed in 10% of tumours at 0-5 cm, 8% at 6-10 cm and 6% at 11-15 cm above the anal verge. Preoperative radiotherapy (RT) reduced the LR rate irrespective of height [0-5 cm: OR 0.50 (0.30-0.83), 6-10 cm: OR 0.42 (0.25-0.71), and 11-15 cm: OR 0.29 (0.13-0.64)]. Patients without preoperative RT had significantly higher LR ...

Our study combined size and timing of the first local recurrence to create a growth rate index (GRI- ratio of size (cm) to timing (mo)) which we analyzed for an association with metastasis. We analyzed 134 locally recurrent tumors from a series of 460 adult patients with soft tissue sarcoma of the extremities and trunk wall who were diagnosed and treated between 1964 and 1990, with a median follow-up of 10 (2-28) years for survivors. None of the patients had metastases at diagnosis. One half (74) of local recurrences were from inadequately treated primaries, one half (71) were associated with metastases, and two thirds (89) were seen in non-center-treated patients. There were equal numbers of patients with GRI ≤ 0.4 (low) and , 0.4 (high). Patients with a low GRI had a better 2-year metastasis-free survival (80 percent) than those with a high GRI (30 percent). High GRIs were associated with large, high grade primary tumors and a short metastasis-free interval in comparison to low GRI tumors. ...

To quantify the influence of RS assay on changing chemotherapy plans in a general practice setting using causal inference methods. We surveyed 3880 newly diagnosed breast cancer patients in Los Angeles and Georgia in 2013-14. We used inverse propensity weighting and multiple imputations to derive complete information for each patient about treatment status with and without testing. A half of the 1545 women eligible for testing (ER+ or PR+, HER2−, and stage I-II) received RS. We estimate that 30% (95% confidence interval (CI) 10-49%) of patients would have changed their treatment selections after RS assay, with 10% (CI 0-20%) being encouraged to undergo chemotherapy and 20% (CI 10-30%) being discouraged from chemotherapy. The subgroups whose treatment selections would be changed the most by RS were patients with positive nodes (44%; CI 24-64%), larger tumor (43% for tumor size |2 cm; CI 23-62%), or younger age (41% for |50 years, CI 23-58%). The assay was associated with a net reduction in chemotherapy

A pelvic MRI scan with IV contrast and rectal balloon is highly effective in identifying local recurrence even at low PSA values in prostate cancer patients.